| Field | Specification |
|---|---|
| Target | |
| Alternative names | Lysine-specific histone demethylase 2; Flavin-containing amine oxidase domain-containing protein 1; Lysine-specific histone demethylase 1B; KDM1B; AOF1; C6orf193; LSD2 |
| Gene ID | |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human LSD2 / AOF1 Histone demethylase that demethylates 'Lys-4' of histone H3, a specific tag for epigenetic transcriptional activation, thereby acting as a corepressor. Required for de novo DNA methylation of a subset of imprinted genes during oogenesis. Acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone ADAG-11 is a rabbit monoclonal antibody that recognizes lysine-specific histone demethylase 2 (gene KDM1B) in human, mouse and rat samples and is validated for Western blot, ICC/IF, immunoprecipitation and flow cytometry. The predicted molecular weight is 92.1 kDa, and the supplier reports an observed band at about 93 kDa.
KDM1B (LSD2) is an FAD-dependent histone demethylase related to LSD1 that removes mono- and dimethyl marks from histone H3 at Lys4, a mark associated with active transcription. It is found in transcribed gene regions and is needed during oocyte growth to establish DNA methylation at a subset of imprinted genes, making it of interest in epigenetics and genomic imprinting.
| Target | Lysine-specific histone demethylase 2 (gene KDM1B; UniProt Q8NB78, human) |
|---|---|
| Clone | ADAG-11 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 92.1 kDa |
| Observed MW | 93 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunocytochemistry / Immunofluorescence | 1:50–1:200 |
| Immunoprecipitation | 1:20 |
| Flow cytometry | 1:20 |
Samples with a confirmed band (WB): human HeLa cells, human K562 cells, human MCF-7 cells, human RT4 cells, HeLa cells, RAW264.7 cells, PC12 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:500 overnight at 4 °C, HRP-conjugated secondary antibody at 1:500, ECL detection.
Immunogen
Synthetic peptide based on the sequence of human LSD2 / AOF1 Histone demethylase that demethylates 'Lys-4' of histone H3, a specific tag for epigenetic transcriptional activation, thereby acting as a corepressor.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places lysine-specific histone demethylase 2 in the nucleus and chromosome. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
